Search

everythinglearnresearchcommunity

for

Search:↓

The antibody 005-C04 blocks prolactin receptors, causing reversible infertility, impaired lactation, and hair regrowth in female mice.

The treatment was effective for advanced non-Hodgkin's lymphomas.

Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

Dupilumab may worsen hair loss in patients with alopecia areata.

Olumiant should be covered for severe alopecia areata if certain conditions are met.

Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.

Dupilumab for skin problems might reactivate hair loss in some patients.

Adalimumab improved folliculitis decalvans in most patients.

Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.

Anti-DFS70 antibodies can help identify nonsystemic autoimmune conditions in SLE patients.

Ruxolitinib cream may help treat severe hair loss in children.

The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

PD‐L1 and PD‐L2 may not effectively control immune activation in alopecia areata.

The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.

The fish oil-based gel with imiquimod improves skin cancer treatment and reduces inflammation.

Treatment with biologic agents can significantly improve psoriasis symptoms, and blood biomarkers could potentially predict individual patient's response to treatment.

Intralesional triamcinolone acetonide can effectively limit the progression of GLPLS.

Dupilumab may worsen Alopecia Areata in some males but improve it in some females, suggesting personalized treatment is needed.

Nivolumab can cause hair loss as a rare side effect.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Abrocitinib may effectively treat stubborn alopecia universalis.